Late stage clinical development plan for cladribine tablets in the treatment of multiple sclerosis

被引：0
|
作者：
Viglietta, V. [1 ]
Greenberg, S. [1 ]
Mikol, D. [1 ]
Weiner, J. [1 ]
Alteri, E. [1 ]
Chang, P. [1 ]
Krumwieh, D. [1 ]
Musch, B. [1 ]
机构：
[1] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2010年 / 257卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P443
引用
收藏
页码：S143 / S144
页数：2
相关论文
共 50 条
  • [21] Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Giovannoni, Gavin
    Nolting, Axel
    Hicking, Christine
    Galazka, Andrew
    Sylvester, Elke
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 : 157 - 167
  • [22] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, Stuart
    Giovannoni, Gavin
    Leist, Thomas
    Syed, Sana
    Nolting, Axel
    Damian, Doris
    Schick, Regina
    NEUROLOGY, 2019, 92 (15)
  • [23] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, S.
    Giovannoni, G.
    Leist, T.
    Syed, S.
    Nolting, A.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 465 - 466
  • [24] Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
    Cook, S.
    Giovannoni, G.
    Leist, T.
    King, J.
    Syed, S.
    Nolting, A.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 469 - 469
  • [25] Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis
    Leist, T.
    Cook, S.
    Comi, G.
    Montalban, X.
    Giovannoni, G.
    Nolting, A.
    Damian, D.
    Syed, S.
    Galazka, A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [26] An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis (RMS)
    Galazka, A.
    Nolting, A.
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 999 - 1000
  • [27] European experience of cladribine tablets in elderly multiple sclerosis: Could it be the last treatment ?
    de Seze, Jerome
    Zecca, Chiara
    Castelnovo, Giovanni
    Ayrignac, Xavier
    Patrick, Vermersch
    Gobbi, Claudio
    Claudia, Mallucci
    Dalliere, Clarisse Carra
    Pierre, Labauge
    Bigaut, Kevin
    Laurent, Kremer
    Collongues, Nicolas
    Lanotte, Livia
    Thouvenot, Eric
    Ernon, Christine
    Dive, Dominique
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 344 - 345
  • [28] Danish experience with cladribine tablets in the treatment of relapsing multiple sclerosis: a nationwide study
    Sorensen, P. S.
    Heick, A.
    Petersen, T.
    Joensen, H.
    Kopp, T. I.
    Sellebjerg, F.
    Magyari, M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 165 - 165
  • [29] Recommendations for the use of cladribine tablets in recurring multiple sclerosis
    Oreja-Guevara, Celia
    Garcia-Merino, Juan A.
    Saiz, Albert
    Rodriguez-Antiguedad, Alfredo
    Alvarez-Cermeno, Jose C.
    Estrada-Perez, Vicente
    Izquierdo, Guillermo
    Fernandez, Oscar
    REVISTA DE NEUROLOGIA, 2019, 69 : S1 - S9
  • [30] Cladribine tablets and multiple sclerosis: NICE technology appraisal
    Gaber, Tarek
    Shippen, Clare
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2018, 22 (01) : 5 - 6
12345